We believe that a highly flexible approach is welcomed by our partners and in our experience delivers the best results.
At each stage of the process we are able to modify and tailor the relationship to the specific needs of each potential partner and depending on what is best for the asset.
The Roche partnering process can be encapsulated in four steps:
Once a new opportunity is identified, we will work alongside our partners with the negotiation team to complete the deal. At the start of negotiations, each project is assigned a Global Alliance Director who will work with the partner through the entire lifetime of the collaboration. We are committed to keeping partners integrally involved with decision making.
Roche Partnering supports Roche’s full value chain, from early-stage Pharma Research and Early Development (pRED) to late-stage Pharma Development, from discovery to commercialisation.
Throughout this process, we also work collaboratively with Genentech Partnering and Diagnostics Business Development to ensure the best outcome for the Roche Group and ultimately for patients.
For early-stage compounds, Roche’s organisations Pharma Research and Early Development (pRED) and Genentech Research and Early Development (gRED) both have full operational autonomy. This is to promote a diversity of research approaches and more innovative outcomes, as well as enabling access to new technologies and promising drug candidates.
For late-stage compounds (typically those that have passed the proof-of-concept stage and are on Phase II clinical trials), our partners can benefit from the agility and expertise of a single organisation, Roche, to carry the relationship forward to compound approval and commercialisation.
Full spectrum partnering
Deal flexibility and M&A competency
Each compound is unique and each partner has different needs; so why should all deals be the same?
We do not have any preconceived notions on the type of deals we should make. Our integrated business development organisation can manage each transaction type and can easily change the structure to suit the needs of each alliance. We are flexible and consider a variety of deal types that range from licensing and acquisitions, to option deals and portfolio agreements, depending on what is best for all parties.
Creative deal structures tailored to each partner
Alliance Management & developing together
At Roche, it is important to us that we and our partners are aligned in our aims and goals.
We are recognised for providing a defined and flexible alliance management structure that ensures the focus remains on the partnership.Mark Noguchi, Head of Alliance Management, about the Role of Alliance Management in Successful Partnerships